Lonza is also producing the vaccine in the U.S. ![]() Separately, Swiss regulators have reportedly allowed Moderna’s contract manufacturer Lonza Group to start producing its Covid-19 vaccine at a plant in Switzerland, which will apparently have a capacity to produce 800,000 doses a day. Moreover, the mRNA technology that Moderna (and Pfizer) are using requires specialized manufacturing equipment. This is positive news, considering that Moderna has no real manufacturing track record and has never produced or sold a commercial drug prior to the Covid-19 shot. The company also said that it was continuing to invest and add staff to potentially produce as much as 1 billion doses for the full year. In the United States, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) voted in December 2020, that the first doses of the vaccine should be prioritized for healthcare workers and residents and staff of nursing homes.Moderna (NASDAQ: MRNA) provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected. Many countries have implemented phased distribution plans that prioritize those at highest risk of complications such as the elderly and those at high risk of exposure and transmission such as healthcare workers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |